Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL (ALL 001)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03962465 |
|
Recruitment Status :
Recruiting
First Posted : May 24, 2019
Last Update Posted : September 11, 2020
|
Sponsor:
University of Virginia
Collaborators:
Pfizer
Vanderbilt University
University of Wisconsin, Madison
Virginia Commonwealth University
Information provided by (Responsible Party):
Michael Douvas, MD, University of Virginia
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 30, 2022 |
| Estimated Study Completion Date : | November 30, 2025 |